Thyrotropin Alfa
Thyrotropin Alfa is a research peptide in the TSH Receptor Agonist class. Thyrotropin alfa is a heterodimeric glycoprotein produced in Chinese hamster ovary cells with the same amino acid sequence as pituitary TSH. It binds the TSH receptor on thyroid follicular cells, increasing iodine uptake and thyroglobulin release.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Approved
- Administration Route
- intramuscular
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Recombinant human thyroid-stimulating hormone approved as an adjunctive diagnostic for serum thyroglobulin testing with or without radioiodine imaging, and as an adjunct to radioiodine ablation of thyroid remnant tissue.
Peptide Library's Thyrotropin Alfa profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- intramuscular
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Thyrotropin Alfa is queued for dosage evidence review.
Compare reported doses across the whole libraryScience
Mechanism of Action
Thyrotropin alfa is a heterodimeric glycoprotein produced in Chinese hamster ovary cells with the same amino acid sequence as pituitary TSH. It binds the TSH receptor on thyroid follicular cells, increasing iodine uptake and thyroglobulin release. This allows follow-up testing without withdrawing thyroid hormone replacement, avoiding the hypothyroid state that withdrawal otherwise requires.
Studies
- [Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg)]
- The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials
- Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy
- Review on the occasion of a decade of recombinant human TSH: prospects and novel uses
- Recombinant human TSH testing for recurrent thyroid cancer: a re-appraisal
Regulatory & research status
Thyrotropin Alfa is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Thyrotropin Alfa: frequently asked questions
What is Thyrotropin Alfa?
Recombinant human thyroid-stimulating hormone approved as an adjunctive diagnostic for serum thyroglobulin testing with or without radioiodine imaging, and as an adjunct to radioiodine ablation of thyroid remnant tissue.
How does Thyrotropin Alfa work?
Thyrotropin alfa is a heterodimeric glycoprotein produced in Chinese hamster ovary cells with the same amino acid sequence as pituitary TSH. It binds the TSH receptor on thyroid follicular cells, increasing iodine uptake and thyroglobulin release.
Is Thyrotropin Alfa FDA approved?
Yes. Thyrotropin Alfa is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Thyrotropin Alfa?
Compounds most often compared with Thyrotropin Alfa include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg)] — Nihon Yakurigaku Zasshi, 2009External reference
- The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials — J Korean Med Sci, 2014External reference
- Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy — Endocrine, 2011External reference
- Review on the occasion of a decade of recombinant human TSH: prospects and novel uses — Thyroid, 2008External reference
- Recombinant human TSH testing for recurrent thyroid cancer: a re-appraisal — Thyroid, 2002External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Thyrotropin Alfa profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Thyrotropin Alfa research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →